{
    "Trade/Device Name(s)": [
        "BOND Ready-to-Use Primary Antibody Progesterone Receptor (16)",
        "Novocastra Liquid Mouse Monoclonal Antibody Progesterone Receptor Clone (16) (Concentrated Liquid Antibody Format)"
    ],
    "Submitter Information": "Leica Biosystems Newcastle Ltd",
    "510(k) Number": "K193393",
    "Predicate Device Reference 510(k) Number(s)": [
        "K171753"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "MXZ"
    ],
    "Summary Letter Date": "December 5, 2019",
    "Summary Letter Received Date": "December 6, 2019",
    "Submission Date": "November 22, 2019",
    "Regulation Number(s)": [
        "21 CFR 864.1860"
    ],
    "Regulation Name(s)": [
        "Immunohistochemistry Reagents And Kits"
    ],
    "Analyte Class(es)": [
        "anatomic pathology"
    ],
    "Analyte(s)": [
        "Progesterone Receptor"
    ],
    "Specimen Type(s)": [
        "Formalin-fixed, paraffin-embedded tissue"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "BOND-MAX",
        "BOND-III"
    ],
    "Method(s)/Technology(ies)": [
        "Immunohistochemistry"
    ],
    "Methodologies": [
        "Qualitative identification by light microscopy",
        "Automated slide staining"
    ],
    "Submission Type(s)": [
        "Reagent",
        "Antibody",
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for BOND Ready-to-Use Primary Antibody Progesterone Receptor (16) and Novocastra Liquid Mouse Monoclonal Antibody Progesterone Receptor Clone (16) for IHC detection of human progesterone receptor in FFPE tissue",
    "Indications for Use Summary": "For qualitative identification of human progesterone receptor in formalin-fixed, paraffin-embedded tissue by immunohistochemical staining as an aid in management, prognosis and prediction of therapy outcome of breast cancer",
    "fda_folder": "Hematology"
}